Show
Sort by
-
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE) : a systematic review and individual patient data meta-analysis from the X-MET collaboration
-
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO Value-Based Radiation Oncology framework
-
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials
-
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial
-
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma : long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
-
Modelling radiotherapy availability in the Asia-Pacific region
-
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI) : an international, paired, non-inferiority, confirmatory study
-
- Journal Article
- A1
- open access
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma : a prospective, open-label, multicentre, phase 3 trial
-
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2) : a multi-dose, open-label, randomised, phase 2 trial
-
Single-arm studies involving patient-reported outcome data in oncology : a literature review on current practice